Gland Pharma Ltd Q1 FY27 Earnings Call Summary

Event Participants

Executives

3

Shriniwas P. Dange (Head, Investor Relations), Ravi Shekhar Mitra (Chief Financial Officer), Srinivas Sadu (Executive Chairman)

Analysts

9

Alankar Garude (KIE), Ashish (Leo Capital), Chintan Sheth (Girik Capital), Karan Vora (Goldman Sachs), Maulik Varia (360 ONE), Neha Manpuria (Bank of America), Rahul Jewani (IIFL Securities), Saion Mukherjee (Nomura Securities), Vivek Gautam (GS Investments)

Financials & KPIs

Geographic & Segment Commentary

CDMO Segment: Revenue of ₹891.5 crore (+20% YoY), representing 50% of total revenues. Growth driven by recent product launches, progression of existing commercial programs, and robust customer engagement. Pipeline remains healthy with a new GLP-1 collaboration signed during the quarter and the announcement of a strategic manufacturing and supply agreement (55 SKUs, ~$90-100 million annualized revenue potential from CY2029).

B2B Segment: Revenue of ₹908.8 crore (+19% YoY), contributing 50% of total revenues. Growth supported by increased demand from existing customers, new contract wins, and higher volumes across key products. Supply reliability and strong execution have enabled market share expansion in select products and markets.

United States: Revenue of ₹981.0 crore (+32% YoY), the largest market. Growth driven by CDMO segment launches (MBI multivitamin, Dalba, Sugarmadex, MVI) and volume expansion. MVI holds CGT exclusivity with no near-term competition. During the quarter: 3 NDAs filed, 7 approvals received, 4 products launched. US run rate ~$110-130 million.

Europe & Other Regulated Markets: Revenue of ₹448.8 crore (+11% YoY). Growth from customer engagement, recent launches, and improved commercial execution. Synxe (France) revenue €48 million with EBITDA of €2 million, impacted by summer heat wave but benefiting from ampoule line ramp-up and operational efficiency during summer shutdown. Four products licensed across European countries with active discussions underway.

Rest of World: Revenue of ₹303.9 crore, broadly flat YoY. Demand healthy across key markets but quarter impacted by supply disruptions in Saudi Arabia with delayed NIPCO tender awards; results expected shortly.

India: Revenue of ₹66.6 crore.

Company-Specific & Strategic Commentary

Strategic Manufacturing Agreement: Executed manufacturing and supply agreement with a leading global specialty pharmaceutical company for technology transfer and manufacturing supply of a portfolio of sterile injectables (55 SKUs, oncology + non-oncology) across vials, lyophilized, ampoules, and prefilled syringes. Annualized revenue potential ~$90-100 million with tech transfer over two years and revenues from CY2029. ~50% US, 30-35% European, and ~20% RoW market split; Synxe supports European warehousing, packaging, and QP release.

GLP-1 Expansion: New CDMO contract signed for SEMA and Tirzepatide for US and EU markets. Transfer activities expected over next quarter or two. Near-term revenue contribution limited (tech transfer fees only); primary volume expected from US launches in FY30-31. Potential upside from customer filing in Canada with possible Q4 FY27 launch.

Liposomal In-Licensing: Agreement with China-based development company for niche liposomal product for US and European markets. Product already approved in China; global market ~$1.6 billion expected to grow to ~$3 billion in three years; US market ~$670 million. Patent protection exists; investment in dedicated compounding suite required. Commercial revenue expected from ~2030.

New England Laboratories Collaboration: Strategic partnership for sterile APIs for microparticle depot products. New suite being built; current capacity fully occupied with 2 APIs and 5-6 additional products in pipeline. Complements internal depot technology platform and positions for end-to-end customer solutions.

Capex Program: Execution commenced on recently announced ₹2,000 crore capex program. ~₹550 crore spend planned for FY27, including ₹165 crore for isolated oncology line (installation by January 2027) and new block at Partsham (vial line BFS + ophthalmic). Brownfield and greenfield expansions prioritized for CDMO demand.

CDMO Growth Strategy: Target 50/50 CDMO/B2B mix for next two years, with CDMO skewing larger by CY2029. Management positioning as end-to-end sterile injectable partner leveraging India cost advantage (Europe sites 5-6x more expensive). Near-term consolidated EBITDA margin target of 30%; mid-to-long-term aspiration of 35%.

European Operations Modernization: Fontenay facility discontinuing older ampoule line, replacing with high-capacity line (addition of ~30 million ampoules annual capacity) entering production early 2027. Heravin facility activity levels increasing steadily with two products launched in 2025 gaining momentum.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

Strategic Manufacturing Agreement Details

• Question: Is the agreement with a big pharma innovator or generic? Where will manufacturing occur and how does revenue ramp to $90-100 million? (Saion Mukherjee, Nomura)
• Answer: (Sadhu) Specialty pharma global company with 30-40% specialty business. Portfolio transferred to Indian sites only. Mix of oncology and non-oncology across formats. Tech transfer starts September 2026, first products in 24 months. ~50% US, 30-35% European, ~20% RoW. Synxe provides European warehousing/packaging/QP release, making the deal viable. Ramp from CY29 to CY30 as filings and approvals progress.
• Question: Could we expect more such contracts? (Saion Mukherjee, Nomura)
• Answer: This is exactly what we're targeting. Large pharma companies procure from 80-100 different sites; we offer end-to-end solutions. Europe sites cost 5-6x more than India, creating structural migration opportunity.

Capex and New Approvals

• Question: Timeline for ₹2,000 crore capex with new initiatives? (Saion Mukherjee, Nomura)
• Answer: (Sadhu & Mitra) Immediate priority: ₹165 crore isolated oncology line for the strategic contract. Building new block for New England Labs API. FY27 capex ~₹550 crore. Brownfield projects at Partsham (vial line BFS + ophthalmic) on track. Further brownfield quickly being evaluated.

FY27 Growth and Senexe Turnaround

• Question: How sustainable is the Senexe turnaround and what's the opportunity size in the US? (Vivek Gautam, GS Investments)
• Answer: (Sadhu) Previously guided 15% CAGR for 4-5 years; now reevaluating at ~20% next four years with new contracts. FY27 constant currency 15% achievable; upside if FDA approves new lines by Aug/Sep. Clearer picture by Sep/Oct.

CDMO Mix and Margin Trajectory

• Question: How does CDMO mix evolve over next 2 years? Are CDMO margins superior? (Neha Manpuria, BofA)
• Answer: (Sadhu) 50/50 split for next two years, CDMO larger by CY2029. Near-term consolidated EBITDA target 30%, mid-long term 35%. Current 28% with room to expand as CDMO commercial contracts ramp.

Senexe Seasonality

• Question: Will Q2 be better than typical seasonal decline given heat wave shifted releases? (Neha Manpuria, BofA)
• Answer: (Sadhu) Better than last year. Quality releases delayed by heat wave will benefit Q2. Maintaining €200M revenue and high single digit margin guidance.

GLP-1 Status

• Question: Status of commercialization and capacity ramp? Revenue potential over 3 years? (Ashish, Leo Capital)
• Answer: (Sadhu) New line on track, exhibit batches for signed customers. New contract for SEMA and Tirzepatide for US and EU. Canada filing by customer could provide Q4 upside. Revenue potential limited near term; main volume from US in FY30-31. Keep expectations conservative.

Senexe Profitability and Launches

• Question: Was heat wave impacting Senexe profitability this quarter? (Chintan Sheth, Girik Capital)
• Answer: (Sadhu) Profitability trend consistent with strategy; aiming for double-digit EBITDA by year-end. Q1 EBITDA €2 million on revenue €48 million.

Base Business Constant Currency

• Question: What is base business growth ex-Synxe and constant currency? (Karan Vora, Goldman Sachs)
• Answer: (Sadhu) Base business grew 24% overall; US grew 32%; constant currency after removing ~5% forex gain: ~19-20%.

Patent-Protected Products in CDMO

• Question: Do we have patent-protected products in CDMO base? (Karan Vora, Goldman Sachs)
• Answer: (Sadhu) Cannot reveal specific products due to customer confidentiality. No innovative products currently. Pipeline discussions on peptide side not yet signed.

New Contracts and Complex Pipeline Timing

• Question: Revenue potential and timelines for New England Labs and China liposomal contracts? (Saion Mukherjee, Nomura)
• Answer: (Sadhu) China liposomal: technology transfer, imported product approved in China, $1.6B global market growing to $3B, US ~$670M. Patent protected, revenue from ~2030. NDDS project: timelines 2028, commercialization 2029, revenue potential $25-30M. New England Labs: extension of existing agreement, new suite being built, current 2 APIs fully occupied, 5-6 additional products in pipeline.
• Question: When do the largest complex pipeline opportunities hit? (Saion Mukherjee, Nomura)
• Answer: Most big products, especially microsphere products, are post-2029. Currently at different stages (chemical, exhibit). These will become the next growth driver after the current 4-year cycle.

Biologics Partnership with Dr. Reddy's

• Question: Any update on Dr. Reddy's biologics partnership and additional capabilities? (Maulik Varia, 360 ONE)
• Answer: (Sadhu) Normal business, generating ~₹50-60 crore per year. Slow ramp in next year or two. No significant new contracts signed recently.

Constant Currency Guidance Consistency

• Question: How does 15% constant currency reconcile with 20% reported growth and ~10% INR depreciation? (Rahul Jewani, IIFL)
• Answer: (Mitra) Constant currency based on dispatch date rates, not uniform average. For projections, we use constant currency only; FX movements are not predicted.

CDMO Margin Profile vs IP-Owned

• Question: Is tech-transfer CDMO margin higher than IP-owned business? (Rahul Jewani, IIFL)
• Answer: (Sadhu) Two CDMO types: D2B tech transfer (smaller portion) and commercialized products transferred from expensive US/Europe manufacturing locations. The latter carries better margin profile given cost arbitrage leverage.

CDMO Growth Drivers

• Question: Top 3-4 factors driving CDMO growth sustainment? (Alankar Garude, KIE)
• Answer: (Sadhu) 1) Portfolio breadth and platform depth, 2) Structural opportunity as pharma exits expensive manufacturing locations (Europe 5-6x India cost), 3) End-market price pressure forcing cost migration, 4) End-to-end solution offering across 3-4 sites under one roof.

Profit Share and NDDS Timelines

• Question: Profit share percentage and NDDS timing? (Alankar Garude, KIE)
• Answer: (Sadhu) Profit share ~9% this quarter. NDDS: development through 2028, commercialization 2029, revenue potential $25-30 million.

Key Takeaway

Gland Pharma delivered a strong start to FY27 with consolidated revenue of ₹1,800.3 crore (+20% YoY), adjusted EBITDA margin expanding to 28% (from 25% in Q1 FY26), and PAT growing 47% YoY to ₹317 crore. Growth was balanced across CDMO (+20% YoY, 50% of revenue) and B2B (+19% YoY) segments, with US revenue surging 32% YoY. Management significantly strengthened the long-term growth platform through a strategic manufacturing and supply agreement with a leading global pharma (55 SKUs, $90-100 million annualized potential from CY2029), a new GLP-1 collaboration for SEMA and Tirzepatide targeting US/EU markets, an in-licensing agreement for a niche liposomal product (~$670 million US market), and a sterile API partnership with New England Laboratories. Near-term guidance maintains ~15% constant currency growth for FY27, with upside to ~20% if FDA approvals for new lines land by Q3; management revised the four-year CAGR outlook to ~20%. Watch items include NIPCO tender delays in Saudi Arabia, execution of the ₹2,000 crore capex program, Synxe's turnaround trajectory toward €200 million revenue with high single-digit EBITDA, and the timing of complex injectable launches (predominantly post-FY29) as the next structural growth driver.